Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With New Mechanism, Can Eisai’s Fycompa Make Its Mark In Epilepsy?

Executive Summary

Efficacy results were not uniformly positive in pivotal trials of newly approved perampanel, but FDA explains that may be due to high placebo rates in some international sites.

Advertisement

Related Content

A Pillar Of Eisai’s Growth Strategy Misses Primary Endpoint In First Phase III Trial
German Joy For Pharma As Drug Discount Prices Stay Hidden
Epilepsy NMEs: A View Of The Playing Field
New Anti-Epileptic Drug Formulations Try To Overcome Tolerability Problems
Specialty Pharma Dominates Epilepsy Market, But Does It Have Resources To Develop Disease-Modifying Agents?
Eisai's Perampanel Phase III Outcomes Show Efficacy, But May Not Meet Company Hype

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054854

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel